American biotechnology company in Carlsbad, California, founded in 1989 as Isis Pharmaceuticals and renamed Ionis in 2015, the leading developer of antisense oligonucleotide medicines. Designs RNA targeted therapies for neurological, cardiovascular, metabolic and rare diseases, with approved medicines including nusinersen for spinal muscular atrophy, inotersen and eplontersen for transthyretin amyloidosis, volanesorsen and olezarsen for severe hypertriglyceridaemia and donidalorsen for hereditary angioedema, and licenses programmes to partners worldwide.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen